vs

Side-by-side financial comparison of COMPX INTERNATIONAL INC (CIX) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

COMPX INTERNATIONAL INC is the larger business by last-quarter revenue ($37.7M vs $19.6M, roughly 1.9× STANDARD BIOTOOLS INC.). COMPX INTERNATIONAL INC runs the higher net margin — 12.4% vs -177.4%, a 189.8% gap on every dollar of revenue. On growth, COMPX INTERNATIONAL INC posted the faster year-over-year revenue change (-1.9% vs -11.5%). COMPX INTERNATIONAL INC produced more free cash flow last quarter ($11.4M vs $-23.1M). Over the past eight quarters, COMPX INTERNATIONAL INC's revenue compounded faster (-0.4% CAGR vs -12.2%).

COMPX International Inc. is a diversified manufacturer of security and control products, including high-performance locking systems, electronic access solutions, ergonomic workstation components, and marine hardware. It primarily serves North American and European markets, catering to commercial, residential, industrial, healthcare, and recreational marine segments.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CIX vs LAB — Head-to-Head

Bigger by revenue
CIX
CIX
1.9× larger
CIX
$37.7M
$19.6M
LAB
Growing faster (revenue YoY)
CIX
CIX
+9.6% gap
CIX
-1.9%
-11.5%
LAB
Higher net margin
CIX
CIX
189.8% more per $
CIX
12.4%
-177.4%
LAB
More free cash flow
CIX
CIX
$34.5M more FCF
CIX
$11.4M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CIX
CIX
Annualised
CIX
-0.4%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CIX
CIX
LAB
LAB
Revenue
$37.7M
$19.6M
Net Profit
$4.7M
$-34.7M
Gross Margin
32.1%
48.5%
Operating Margin
15.0%
-168.5%
Net Margin
12.4%
-177.4%
Revenue YoY
-1.9%
-11.5%
Net Profit YoY
3.6%
-28.8%
EPS (diluted)
$0.38
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIX
CIX
LAB
LAB
Q4 25
$37.7M
Q3 25
$40.0M
$19.6M
Q2 25
$40.4M
$21.8M
Q1 25
$40.3M
$40.8M
Q4 24
$38.4M
Q3 24
$33.7M
$22.1M
Q2 24
$35.9M
$22.5M
Q1 24
$38.0M
$45.5M
Net Profit
CIX
CIX
LAB
LAB
Q4 25
$4.7M
Q3 25
$4.2M
$-34.7M
Q2 25
$5.5M
$-33.5M
Q1 25
$5.1M
$-26.0M
Q4 24
$4.5M
Q3 24
$3.5M
$-26.9M
Q2 24
$4.8M
$-45.7M
Q1 24
$3.8M
$-32.2M
Gross Margin
CIX
CIX
LAB
LAB
Q4 25
32.1%
Q3 25
27.6%
48.5%
Q2 25
31.9%
48.8%
Q1 25
30.2%
48.4%
Q4 24
28.8%
Q3 24
28.1%
54.9%
Q2 24
31.1%
46.1%
Q1 24
25.5%
53.1%
Operating Margin
CIX
CIX
LAB
LAB
Q4 25
15.0%
Q3 25
11.9%
-168.5%
Q2 25
15.7%
-118.1%
Q1 25
14.6%
-80.8%
Q4 24
12.7%
Q3 24
9.9%
-120.9%
Q2 24
14.2%
-134.5%
Q1 24
9.8%
-132.2%
Net Margin
CIX
CIX
LAB
LAB
Q4 25
12.4%
Q3 25
10.6%
-177.4%
Q2 25
13.5%
-153.7%
Q1 25
12.7%
-63.8%
Q4 24
11.7%
Q3 24
10.3%
-122.0%
Q2 24
13.5%
-203.3%
Q1 24
9.9%
-70.6%
EPS (diluted)
CIX
CIX
LAB
LAB
Q4 25
$0.38
Q3 25
$0.34
$-0.09
Q2 25
$0.44
$-0.09
Q1 25
$0.42
$-0.07
Q4 24
$0.37
Q3 24
$0.28
$-0.07
Q2 24
$0.39
$-0.12
Q1 24
$0.31
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIX
CIX
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$54.1M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$138.6M
$399.7M
Total Assets
$156.2M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIX
CIX
LAB
LAB
Q4 25
$54.1M
Q3 25
$46.3M
$129.4M
Q2 25
$56.2M
$158.6M
Q1 25
$56.1M
$150.9M
Q4 24
$60.8M
Q3 24
$58.8M
$210.6M
Q2 24
$82.1M
$269.8M
Q1 24
$75.6M
$287.1M
Total Debt
CIX
CIX
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CIX
CIX
LAB
LAB
Q4 25
$138.6M
Q3 25
$137.7M
$399.7M
Q2 25
$149.5M
$424.5M
Q1 25
$147.6M
$454.6M
Q4 24
$146.1M
Q3 24
$145.3M
$489.3M
Q2 24
$170.2M
$510.3M
Q1 24
$168.9M
$577.3M
Total Assets
CIX
CIX
LAB
LAB
Q4 25
$156.2M
Q3 25
$153.7M
$539.6M
Q2 25
$164.8M
$557.0M
Q1 25
$162.2M
$579.6M
Q4 24
$163.0M
Q3 24
$160.1M
$681.5M
Q2 24
$185.1M
$708.7M
Q1 24
$181.7M
$777.7M
Debt / Equity
CIX
CIX
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIX
CIX
LAB
LAB
Operating Cash FlowLast quarter
$12.0M
$-22.2M
Free Cash FlowOCF − Capex
$11.4M
$-23.1M
FCF MarginFCF / Revenue
30.3%
-118.1%
Capex IntensityCapex / Revenue
1.6%
4.5%
Cash ConversionOCF / Net Profit
2.57×
TTM Free Cash FlowTrailing 4 quarters
$19.1M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIX
CIX
LAB
LAB
Q4 25
$12.0M
Q3 25
$6.3M
$-22.2M
Q2 25
$4.7M
$-20.7M
Q1 25
$-137.0K
$-30.3M
Q4 24
$7.3M
Q3 24
$4.1M
$-27.9M
Q2 24
$9.8M
$-39.0M
Q1 24
$1.7M
$-62.5M
Free Cash Flow
CIX
CIX
LAB
LAB
Q4 25
$11.4M
Q3 25
$5.3M
$-23.1M
Q2 25
$3.4M
$-22.6M
Q1 25
$-959.0K
$-35.3M
Q4 24
$7.1M
Q3 24
$3.6M
$-30.1M
Q2 24
$9.4M
$-41.0M
Q1 24
$1.4M
$-63.3M
FCF Margin
CIX
CIX
LAB
LAB
Q4 25
30.3%
Q3 25
13.2%
-118.1%
Q2 25
8.4%
-103.6%
Q1 25
-2.4%
-86.6%
Q4 24
18.5%
Q3 24
10.8%
-136.4%
Q2 24
26.2%
-182.2%
Q1 24
3.6%
-138.9%
Capex Intensity
CIX
CIX
LAB
LAB
Q4 25
1.6%
Q3 25
2.5%
4.5%
Q2 25
3.3%
8.7%
Q1 25
2.0%
12.4%
Q4 24
0.6%
Q3 24
1.4%
10.2%
Q2 24
1.2%
8.6%
Q1 24
0.8%
1.7%
Cash Conversion
CIX
CIX
LAB
LAB
Q4 25
2.57×
Q3 25
1.48×
Q2 25
0.87×
Q1 25
-0.03×
Q4 24
1.62×
Q3 24
1.18×
Q2 24
2.03×
Q1 24
0.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CIX
CIX

Security Products$29.5M78%
Marine Components$8.2M22%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons